TOKYO, JAPAN - Jan. 31, 2017 - Terumo Corporation (TSE: 4543) announced today that its Yangon Branch opened for business in January 2017.
In Myanmar, economic growth has been strong1 and healthcare market has been expanding since the country's transition from military rule to a civilian government in 2011. Growth is projected to continue in the future, but maintenance of healthcare systems and facilities has been falling behind.2
Terumo began doing business in Myanmar in the 1990s,3 and has continuously engaged in commercial activities in the country since that time. As a result, Terumo now has substantial market shares in Myanmar for a wide range of products, including interventional systems, oxygenators, blood bags, blood glucose monitors, and infusion systems. By opening a branch in Yangon, the country's largest city, Terumo intends to establish more locally based operations and expand its business while also aiming to contribute to the development of medical technologies in the country by offering healthcare training and other initiatives.
Overview of the Yangon Branch
|Name:||Terumo Singapore Pte. Ltd. (Yangon Branch)|
|Date of establishment:||June 23, 2016|
|Date of opening:||January 9, 2017|
|Number of employees:||3 (As of January, 2017)|
Real GDP is forecast to grow between 6 - 9% annually according to the International Monetary Fund's World Economic Outlook Database
According to a report on global healthcare conditions published by Japan's Ministry of Foreign Affairs
Sales are mainly carried out through local sales agents
Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.